Company: VRE
Filing Date: 2025-03-03
Form Type: S-3ASR
Source: 0001104659-25-019837
Chunk: 2

Company: Veris Residential, Inc.
Filing Date: 2025-03-03
Form: S-3ASR
Chunk 2
---
 Common units are redeemable by the selling stockholders at their option, subject to certain restrictions, on
the basis of one common unit for either one share of our common stock or, at our sole election as general partner of the Operating Partnership,
cash equal to the fair market value of a share of our common stock at the time of the redemption. All net proceeds from the sale
of the shares of our common stock offered by this prospectus will go to the selling stockholders. We will not receive any proceeds
from such sales.

The selling stockholders may offer their shares
of common stock through public or private transactions, in the over-the-counter markets or on any exchanges on which our common stock
is traded at the time of sale, at prevailing market prices or at privately negotiated prices. The selling stockholders may engage
brokers or dealers who may receive commissions or discounts from the selling stockholders. We will pay substantially all of the
expenses incident to the registration of such shares, except for selling commissions.

We are a Maryland corporation incorporated in 1994.
Our executive offices are located at Harborside 3, 210 Hudson Street, Suite 400, Jersey City, New Jersey 07311, and our telephone number
is (732) 590-1010. We maintain an Internet website at www.verisresidential.com. We have not incorporated by reference
into this prospectus the information in, or that can be accessed through, our website, and you should not consider it to be a part of
this prospectus.

Our common stock is listed on The New York Stock
Exchange under the symbol “VRE.” The closing price of our common stock as reported on The New York Stock Exchange on
February 28, 2025 was $16.93 per share.

Investment in our common stock involves certain risks, including those described beginning on page 9 of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024. You should consider such risk factors before investing in our common stock.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.

<div align='center'>The date of this prospectus is March 3, 2025</div>

You should rely only on the information contained in or incorporated by reference in this prospectus. We have not authorized anyone to provide you with different